Cullinan Therapeutics Q2 2026 net loss $53.7M; cash $356M; pipeline on track

Cullinan Therapeutics, Inc.

Net loss $53.7M vs $70.1M YoY; R&D expenses $44.4M vs $61.0M; G&A $12.8M vs $14.8M.
Cash and investments $356M as of June 30, 2026; runway into 2029.
CLN-049 Phase 2 in R/R AML to start Q3 2026 after positive FDA End-of-Phase 1 meeting.
CLN-978 multi-dose data in RA Q3 2026, SLE Q4 2026; Phase 2 expansion early 2027.
Zipalertinib NDA accepted; PDUFA Feb 27, 2027; Cullinan eligible for $30M on 2L approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.